Jump to main content
Takeda will discontinue global manufacturing of NATPARA by the end of 2024. Learn How This May Affect You


Managing hypoparathyroidism requires careful monitoring2

In stable patients:

  • Serum calcium, phosphorous/phosphate, magnesium, BUN/creatinine and eGFR at least yearly
  • 24-hour urine collection for calcium and creatinine yearly

During dose adjustments:

  • More frequent monitoring, often several times per week, until a stable serum calcium concentration is achieved

For dosing and monitoring specific to NATPARA, click here.

Aim for low-normal, albumin-corrected total serum calcium levels2,3

For patients being treated for hypoparathyroidism, serum calcium levels are typically maintained at the lower end of the normal range (approximately 8.0 to 9.0 mg/dL).2

Albumin-corrected total serum
calcium levels1-4

Graph showing the target calcium range for people being targeted for hypoparathyroidism.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Brandi ML, Bilezikian JP, Shock D, et al. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi: 10.1210/jc.2015-3907. 3. Shoback D. N Engl J Med. 2008;359(4):391-403. 4. Fong J, Khan A. Can Fam Physician. 2012;58(2):158-162.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.